Why the Mobi recall is front and center for Tandem Diabetes Care
Tandem Diabetes Care (TNDM) is under close watch after recalling about 81,000 Mobi insulin pumps due to false occlusion alarms that can halt insulin delivery and have led to over 200 reported adverse events.
The issue stems from increased friction in the pump’s drive module, which can trigger a blockage warning even when insulin flow is normal and cause the device to stop dosing until the user intervenes.
Users have been told to treat every occlusion alert as real, to keep backup insulin options available, and to contact Tandem for pump exchanges if alarms become frequent or disruptive to treatment.
The Mobi recall arrives after a tough stretch for Tandem Diabetes Care’s shareholders, with the share price falling 22.9% over 3 months and 18.8% year to date. The 1-year total shareholder return is roughly flat, which hints at fading momentum after earlier gains.
Stress test your watchlist by comparing Tandem Diabetes Care with 29 resilient stocks with low risk scores that may better hold up when product recalls or stock-specific shocks hit.
The recall, the share price slide and the earnings reset leave Tandem Diabetes Care looking very different at US$17.51. Is this a reasonable entry point now, or does waiting for a lower price make more sense?
Most Popular Narrative: 36.9% Undervalued
The analyst consensus Narrative on Simply Wall St compares a fair value of $27.76 for Tandem Diabetes Care with the recent $17.51 share price. This points to a sizeable valuation gap and places greater focus on how margin progress and recurring revenue develop from here.
Structural margin improvement efforts are gaining traction as gross margin has reached the mid to high 50% range, adjusted EBITDA margins have turned positive for four consecutive quarters, and operating expenses and stock based compensation are being held in check. Together, these factors can support higher net margins and stronger earnings power if revenue continues to scale.
See why 8 investors see Tandem Diabetes Care as 37% undervalued.
Result: Fair Value of $27.76 (UNDERVALUED)
Still, the recall overhang on Mobi and third party infusion set constraints could pressure Tandem Diabetes Care by disrupting pump usage and denting confidence in future upgrades.
Find out about the key risks to this Tandem Diabetes Care narrative.
Next Steps
If the Tandem Diabetes Care story so far feels finely balanced between concern and opportunity, use the numbers to pressure test your own thesis and move early. To see what optimism is already priced into the business, start with the 3 key rewards.
Looking for more investment ideas beyond Tandem Diabetes Care?
If Tandem Diabetes Care is already on your radar, broaden your opportunity set now so you are not relying on a single story to work out.
- Target steadier compounding by scanning companies that combine quality metrics with attractive pricing through the 32 high quality undervalued stocks.
- Prioritise resilience under pressure and hunt for businesses with stronger cushions against shocks using the list of solid balance sheet and fundamentals (23 results).
- Hunt for early-stage potential where fundamentals already look constructive by reviewing the 11 elite penny stocks with strong financials.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com